GLOBAL WHOLEHEALTH PTNRS - GWHP STOCK NEWS

Global WholeHealth Partners Corp (GWHP: OTC) is enhancing COVID-19 testing by providing services directly to schools and workplaces. The company utilizes a CLIA WAIVED lab to conduct tests for COVID-19 Antigen and Antibody, along with other diagnostic tests. With an expansive lineup of 56 FDA-approved products, including 15 POC tests, Global is committed to offering rapid testing solutions. The company emphasizes the importance of swift results to help curb the spread of the virus, leveraging advanced IVD technology for detecting SARS-CoV-2 antibodies.

Global WholeHealth Partners Corp (OTC: GWHP) announces a significant advancement in diagnosing autism spectrum disorder (ASD) by utilizing a Micro-Well Reader or Lateral Flow Test. With CDC data revealing that about 1 in 54 children in the U.S. are diagnosed with ASD, the company aims to improve early detection, which is vital for patient quality of life. Currently, GWHP has over 70 FDA-approved diagnostic tests and can produce up to 1 million tests per day. The company is collaborating with Nunzia Pharmaceutical on future ASD treatments.

Global WholeHealth Partners Corp (OTC: GWHP) has secured its first purchase order from Nunzia Pharmaceutical for its FDA Approved Diagnostic Tests aimed at neurological diseases. This partnership includes sales of vaccines and nutraceuticals targeting stress and anxiety, aligning with products for Alzheimer’s and Parkinson’s. The company currently boasts 56 FDA-approved products and plans to expand its testing capabilities, aiming for 1 million tests per day. CEO Charles Strongo highlights the focus on rapid diagnostic tests and ongoing R&D.

Global WholeHealth Partners Corp (GWHP) announces a medical breakthrough in the diagnosis of Parkinson's disease, utilizing a Micro-Well Reader or Lateral Flow Test to identify specific brain enzymes linked to the disease. This development comes during Parkinson's Awareness Month, amidst rising concerns over increasing Parkinson's cases, which have surged 35% in the last decade in the US alone. The company aims to enhance early detection of Parkinson's and expand its range of over 70 FDA-approved diagnostic tests. CEO Charles Strongo emphasizes the need for accurate data to combat this growing health issue.

Classworx, Inc. (OTC PINK:CHNO) has published an interview with Charles Strongo, CEO of Global WholeHealth Partners (OTC PINK:GWHP), on April 26, 2021. The discussion focused on FDA-approved diagnostic tests and is available on Classworx's YouTube channel. Additionally, Classworx has officially changed its name from Chill N Out Cryotherapy, Inc. and is awaiting financial approvals. Global WholeHealth Partners aims to improve healthcare through advanced diagnostic technologies, addressing significant diseases efficiently.

Global WholeHealth Partners Corp. (GWHP) has announced a partnership with Nunzia Pharmaceutical to market products aimed at neurological disorders. This collaboration includes a nutraceutical for anxiety and stress, along with FDA-approved diagnostic tests. The company currently offers more than 70 FDA-approved tests and can scale up to 1 million tests daily. GWHP aims to lead in in-vitro diagnostic tests while addressing nutritional deficiencies linked to dementia-like symptoms. The firm emphasizes its commitment to research and development to maintain competitive advantages.

Global WholeHealth Partners (OTC:GWHP) announces a significant advancement in Dementia diagnostic testing, utilizing a Micro-Well Reader and Lateral Flow Test to assess brain enzymes for diagnosis. This breakthrough was detailed in an 8K filing on March 21, 2021. CEO Charles Strongo highlighted a partnership with Nunzia Pharmaceutical, enhancing capabilities in neurological disorder testing. The company currently holds 56 FDA-approved products for consumer and professional use, with a production capacity of up to 1 million tests daily, supporting early detection initiatives crucial for patient care.

Classworx, Inc. (OTC PINK:CHNO) will host an interview with Charles Strongo, CEO of Global WholeHealth Partners (OTC PINK:GWHP) on April 26, 2021, at 10 AM EST. The discussion will focus on FDA-approved diagnostic tests. Classworx, a virtual instructor directory, allows instructors to host events and earn from attendees. This platform is designed for a variety of users, including businesses and individuals looking for virtual engagement. The interview is free for attendees, encouraging diverse participation.

Global WholeHealth Partners Corp. (OTC: GWHP) announces a significant advancement in Alzheimer's disease diagnostics, introducing a Micro-Well Reader and Lateral Flow Test for early detection. CEO Charles Strongo emphasizes the importance of early diagnosis, especially with the growing number of Alzheimer's cases, currently affecting over 6 million Americans. The company aims to enhance its diagnostic offerings while partnering with Nunzia Pharmaceutical for neurological disorders, maintaining a focus on innovation in the medical testing industry.